PanOph

Cavernous sinus syndrome

Neuro-Ophthalmology

Key Points

  • •Cavernous sinus syndrome presents with painful ophthalmoplegia involving CN III, IV, VI, V1/V2, and sympathetic fibres — CN VI is the most commonly affected nerve
  • •Bilateral involvement in a febrile patient is pathognomonic of septic cavernous sinus thrombosis (spread via intercavernous sinuses)
  • •Tolosa-Hunt syndrome is a diagnosis of exclusion — dramatic pain relief within 72 hours of systemic steroids is characteristic
  • •CCF: direct (high-flow, post-traumatic) requires urgent embolisation; indirect (low-flow, dural) may resolve spontaneously in up to 50%
  • •MRI with gadolinium is the investigation of choice; DSA is the gold standard for CCF classification
1. Definition

Cavernous sinus syndrome (CSS) is a clinical constellation resulting from pathology within or adjacent to the cavernous sinus, producing ophthalmoplegia (CN III, IV, VI), sensory loss (CN V1 and V2), and sympathetic dysfunction (Horner syndrome). The cavernous sinus is a paired dural venous sinus flanking the sella turcica, through which pass cranial nerves III, IV, V1, V2, and VI alongside the internal carotid artery (ICA) and sympathetic plexus. Any lesion within this confined space can produce a characteristic painful ophthalmoplegia with multiple cranial nerve palsies.

2. Epidemiology

Incidence varies by aetiology. Cavernous sinus thrombosis (CST) accounts for ~1–2% of cerebral venous thromboses. Tumours (meningioma, pituitary adenoma, nasopharyngeal carcinoma, metastases) are the most common cause overall (40%), followed by vascular lesions (30%, including carotid-cavernous fistula and aneurysm), inflammation (15%, Tolosa-Hunt syndrome), and infection (10%, septic CST).

CST from paranasal sinusitis is now rare in the antibiotic era but remains important due to high mortality (~30%) if untreated.

No clear sex predilection overall; Tolosa-Hunt has equal sex incidence, whereas carotid-cavernous fistula (indirect/dural type) is more common in postmenopausal women.

Mean age at presentation varies: infectious CST — young adults; Tolosa-Hunt — 40–60 years; tumours — any age.

3. Aetiology and causes

Vascular:

  • Carotid-cavernous fistula (CCF): direct (post-traumatic, high-flow) or indirect/dural (spontaneous, low-flow)
  • ICA aneurysm (intracavernous segment) — most commonly affects CN VI (runs freely within the sinus)
  • Cavernous sinus thrombosis (septic or aseptic)

Neoplastic:

  • Meningioma (sphenoid wing, cavernous sinus)
  • Pituitary adenoma with lateral extension
  • Nasopharyngeal carcinoma — direct invasion
  • Metastases (breast, lung most common)
  • Lymphoma, craniopharyngioma, chordoma

Inflammatory/Autoimmune:

  • Tolosa-Hunt syndrome — idiopathic granulomatous inflammation of the cavernous sinus; diagnosis of exclusion
  • Sarcoidosis, granulomatosis with polyangiitis (GPA), IgG4-related disease

Infectious:

  • Septic cavernous sinus thrombosis — most commonly from paranasal sinusitis (sphenoid/ethmoid), orbital cellulitis, dental infection, or facial furuncle (danger triangle of the face)
  • Mucormycosis — in diabetic ketoacidosis / immunocompromised; black eschar pathognomonic
  • Aspergillosis, tuberculosis, herpes zoster (V1)

Traumatic:

  • Basal skull fracture → direct CCF
  • Iatrogenic (post-surgical, post-endovascular)
4. Pathogenesis

The cavernous sinus is a trabeculated venous space between periosteal and meningeal layers of dura. Within its lateral wall lie CN III (superior), CN IV (below III), and CN V1 and V2 (inferior). CN VI and the ICA with its sympathetic plexus run through the centre of the sinus — making CN VI the most vulnerable to compression.

Infectious CST: Infection spreads via valveless emissary veins (angular vein, ophthalmic veins, pterygoid plexus) from the danger triangle of the face (area between the medial canthi and upper lip). Septic thrombus forms within the sinus → inflammation and oedema compress traversing cranial nerves → thrombophlebitis may extend to the contralateral cavernous sinus via intercavernous sinuses (bilateral involvement is pathognomonic of CST).

Tumours: Mass effect compresses cranial nerves in order of anatomical vulnerability: CN VI (free-floating in the sinus) → CN III, IV (in the lateral wall) → CN V1, V2.

Tolosa-Hunt: Granulomatous inflammation of the cavernous sinus wall causes painful ophthalmoplegia that responds dramatically to corticosteroids (within 72 hours).

CCF: Abnormal arteriovenous communication between ICA (or its meningeal branches) and the cavernous sinus → arterialization of orbital veins → raised episcleral venous pressure → proptosis, chemosis, raised IOP, and cranial nerve palsies.

5. Classification

By aetiology:

  • Vascular (CCF, aneurysm, thrombosis)
  • Neoplastic (primary or metastatic)
  • Inflammatory (Tolosa-Hunt, sarcoidosis, IgG4)
  • Infectious (septic CST, mucormycosis)
  • Traumatic

By anatomical involvement:

  • Anterior cavernous sinus: CN III, IV, VI, V1 predominantly → orbital apex overlap
  • Posterior cavernous sinus: CN V2 involvement, Meckel cave extension
  • Complete CSS: all nerves involved + sympathetic

Carotid-cavernous fistula classification (Barrow):

  • Type A: Direct — ICA to cavernous sinus (high-flow, post-traumatic)
  • Type B: Dural — ICA meningeal branches to cavernous sinus (low-flow)
  • Type C: Dural — ECA meningeal branches to cavernous sinus
  • Type D: Dural — mixed ICA + ECA meningeal branches (most common indirect type)

Tolosa-Hunt syndrome (ICHD-3 criteria):

  1. Unilateral headache/orbital pain
  2. Granulomatous inflammation of cavernous sinus on MRI/biopsy
  3. Paresis of one or more of CN III, IV, VI
  4. Symptoms correlate with inflammation
  5. Not better accounted for by another diagnosis
6. Risk factors and associations
  • Septic CST: paranasal sinusitis (especially sphenoid), orbital cellulitis, dental infections, facial furunculosis (danger triangle), otitis media
  • Mucormycosis: poorly controlled diabetes mellitus (especially DKA), haematological malignancies, organ transplant, immunosuppression
  • CCF (direct): head trauma, especially basal skull fracture
  • CCF (indirect/dural): postmenopausal women, hypertension, atherosclerosis, connective tissue disorders (Ehlers-Danlos type IV)
  • Tolosa-Hunt: no specific risk factors; diagnosis of exclusion
  • Tumours: prior malignancy (metastases), NF2 (meningioma), MEN1 (pituitary adenoma)
  • Aseptic CST: hypercoagulable states (pregnancy, OCP, malignancy, antiphospholipid syndrome), dehydration
7. Clinical features

Core features (present in all aetiologies):

  • Painful ophthalmoplegia — hallmark of CSS
  • CN VI palsy — most common single cranial nerve affected (CN VI runs freely through the sinus, most vulnerable)
  • CN III palsy — ptosis, 'down and out' eye, mydriasis (may be partial)
  • CN IV palsy — vertical diplopia, head tilt
  • CN V1 sensory loss — forehead/upper eyelid numbness, reduced corneal reflex
  • CN V2 sensory loss — cheek/upper lip numbness
  • Horner syndrome (ipsilateral) — miosis, ptosis, anhidrosis (postganglionic sympathetic disruption)

Aetiology-specific features:

Septic CST:

  • Acute onset, high fever, toxic appearance
  • Proptosis, chemosis, periorbital oedema
  • Bilateral involvement (pathognomonic — spread via intercavernous sinuses)
  • Papilloedema, retinal haemorrhages
  • Meningeal signs if concurrent meningitis

CCF:

  • Pulsatile proptosis, orbital bruit (auscultate over the globe)
  • Corkscrew conjunctival vessels (arterialized episcleral veins)
  • Raised IOP (from elevated episcleral venous pressure)
  • Glaucoma (secondary open-angle mechanism)
  • Optic disc oedema, retinal venous congestion

Tolosa-Hunt:

  • Severe unilateral orbital/periorbital pain
  • Ophthalmoplegia developing within 2 weeks of pain onset
  • Dramatic response to systemic corticosteroids within 72 hours (diagnostic clue)
  • Recurrent-remitting course

Tumour:

  • Progressive, painless (or slowly painful) ophthalmoplegia
  • Insidious onset over weeks to months
  • Numb chin syndrome (V3) if nasopharyngeal carcinoma

Exam pearl — Pupil in CSS:

  • CN III palsy → mydriasis (parasympathetic dysfunction)
  • Sympathetic damage → miosis (Horner)
  • When both are affected → pupil may be mid-dilated and poorly reactive (opposing forces cancel out)
8. Investigations

Imaging:

  • MRI brain with gadolinium — investigation of choice; demonstrates cavernous sinus enhancement, mass lesion, granulomatous tissue (Tolosa-Hunt), thrombosis
  • MR angiography (MRA) / CT angiography (CTA) — for CCF, ICA aneurysm
  • Digital subtraction angiography (DSA) — gold standard for CCF classification (Barrow types A–D) and therapeutic embolisation planning
  • CT paranasal sinuses — essential if septic CST suspected (look for sphenoid/ethmoid sinusitis)
  • MR venography (MRV) — to confirm sinus thrombosis

Blood investigations:

  • FBC, ESR, CRP — raised in infection/inflammation
  • Blood cultures — mandatory in suspected septic CST
  • Coagulation screen, D-dimer — if aseptic thrombosis suspected
  • HbA1c, blood glucose — to exclude diabetes (mucormycosis risk)
  • ACE, lysozyme — sarcoidosis
  • ANCA — GPA
  • IgG4 levels — IgG4-related disease
  • Tumour markers — as indicated

Other:

  • Cavernous sinus biopsy — if diagnosis unclear after imaging and serological workup; reserved for cases where Tolosa-Hunt criteria not met or lymphoma/IgG4 suspected
  • CSF analysis — if meningitis suspected (septic CST)
  • Nasal endoscopy — if nasopharyngeal carcinoma suspected
  • Orbital colour Doppler ultrasound — reversed flow in superior ophthalmic vein (SOV) diagnostic of CCF
9. Differential diagnosis

Orbital apex syndrome:

  • Involves CN II (optic nerve) in addition to III, IV, V1, VI
  • Distinguishing factor: visual loss and optic disc changes present
  • No CN V2 involvement (V2 enters foramen rotundum, not the orbital apex)

Superior orbital fissure syndrome:

  • CN III, IV, V1, VI involvement (similar to CSS) but NO V2, NO sympathetic involvement
  • Distinguishing factor: no cheek numbness (V2 spared), no Horner syndrome

Orbital cellulitis:

  • Proptosis, ophthalmoplegia, chemosis, fever
  • Distinguishing factor: usually unilateral; CT shows preseptal/postseptal orbital fat stranding rather than cavernous sinus enhancement

Myasthenia gravis:

  • Painless ophthalmoplegia, ptosis, variable diplopia
  • Distinguishing factor: NO sensory loss (V1/V2), NO pupil involvement, fatigability, positive ice test/AChR antibodies

Miller Fisher syndrome:

  • Ophthalmoplegia + ataxia + areflexia
  • Distinguishing factor: bilateral, descending, anti-GQ1b antibodies; NO pain or sensory loss in V distribution

Posterior communicating artery aneurysm:

  • Isolated painful CN III palsy with mydriasis
  • Distinguishing factor: isolated CN III involvement only (no IV, VI, or V involvement); a neurosurgical emergency
10. Complications
  • Visual loss: optic neuropathy from compression or ischaemia, secondary glaucoma (CCF)
  • Cerebral complications (septic CST): meningitis, brain abscess, stroke (ICA thrombosis/occlusion)
  • Contralateral spread (septic CST): via intercavernous sinuses → bilateral CSS
  • Pituitary apoplexy: if pituitary adenoma haemorrhages → acute bitemporal hemianopia + CSS
  • Cranial nerve damage (permanent): particularly CN VI, leading to persistent diplopia
  • Raised IOP / glaucoma (CCF): from elevated episcleral venous pressure
  • Optic disc oedema → optic atrophy
  • Mortality: septic CST carries =~30% mortality even with treatment; mucormycosis 50–80%== mortality if not promptly treated
  • Recurrence: Tolosa-Hunt syndrome recurs in 40–50% of patients
  • Corneal exposure: combined CN III (levator) + CN V1 (corneal sensation) damage → neurotrophic + exposure keratopathy
11. Management

General principles:

  • Urgent neuroimaging (MRI + MRA/CTA) in ALL patients presenting with painful ophthalmoplegia
  • Treat the underlying cause

Septic CST:

  • IV broad-spectrum antibiotics (empirical: vancomycin + ceftriaxone + metronidazole) — cover Staph aureus, Streptococci, anaerobes, Gram-negatives
  • Start antibiotics BEFORE imaging results in febrile patient with CSS signs
  • Source control: surgical drainage of paranasal sinuses, orbital abscess if present
  • Anticoagulation (heparin): controversial; consider if no haemorrhagic infarct on imaging and progressive deterioration despite antibiotics
  • Corticosteroids: adjunctive if significant oedema/inflammation, AFTER adequate antimicrobial cover

Mucormycosis:

  • IV amphotericin B (liposomal formulation preferred — less nephrotoxic)
  • Aggressive surgical debridement (sino-orbital)
  • Correct underlying immunosuppression (treat DKA, reduce immunosuppressants)
  • Posaconazole as step-down oral therapy

CCF:

  • Direct (Type A): urgent endovascular embolisation — detachable balloons or coils via transarterial approach
  • Indirect (Types B–D): observation initially (up to 50% resolve spontaneously); if persistent → transvenous embolisation via inferior petrosal sinus
  • Monitor IOP and treat raised pressure
  • Protect the cornea if exposure

Tolosa-Hunt:

  • Systemic corticosteroids: prednisolone 1 mg/kg/day — dramatic pain relief within 72 hours (diagnostic and therapeutic)
  • Taper over 4–6 weeks
  • Steroid-sparing agents (azathioprine, methotrexate) if recurrent
  • Must exclude other causes first — Tolosa-Hunt is a diagnosis of exclusion

Tumour:

  • Neurosurgical/oncological management as appropriate
  • Pituitary adenoma: transsphenoidal surgery, medical therapy (dopamine agonists for prolactinoma)
  • Meningioma: surgery +/- radiotherapy
  • Metastases: radiation, systemic chemotherapy

Supportive care:

  • Prism glasses or occlusion for diplopia management
  • Lubricants for corneal protection
  • Cycloplegics if concurrent anterior segment inflammation
12. Prognosis

Septic CST: mortality ~30% with treatment; morbidity significant — 50–80% have residual cranial nerve deficits.

Mucormycosis: mortality 50–80% without treatment; improved to 30–50% with early amphotericin B + debridement; prognosis closely tied to control of underlying disease (DKA correction).

CCF (direct): excellent prognosis with successful endovascular embolisation; >90% cure rate. Untreated → progressive visual loss, intractable glaucoma.

CCF (indirect): 50% resolve spontaneously; remainder require intervention with good outcomes.

Tolosa-Hunt: pain resolves within 72 hours of steroids in most cases; ophthalmoplegia resolves over weeks. Recurrence rate ~40–50%.

Tumour-related: depends on histology; meningiomas generally favourable; metastases carry guarded prognosis.

Overall, CN VI recovery is often the slowest and most incomplete.

Clinical Pearls

1
The danger triangle of the face (medial canthi to upper lip) drains via the angular and ophthalmic veins (valveless) directly into the cavernous sinus — never squeeze a furuncle in this area.
2
CN VI palsy is the first nerve affected in most cavernous sinus lesions because it runs freely through the centre of the sinus (not embedded in the lateral wall like CN III, IV, V1, V2).
3
A mid-dilated, poorly reactive pupil in CSS results from simultaneous parasympathetic (CN III) and sympathetic damage — the opposing forces of mydriasis and miosis cancel out.
4
Corkscrew conjunctival vessels (arterialized episcleral veins) + pulsatile proptosis + orbital bruit = classic triad of carotid-cavernous fistula. Confirm with reversed SOV flow on orbital Doppler.
5
In septic CST, always image the paranasal sinuses — sphenoid sinusitis is the most common source and requires concurrent surgical drainage alongside IV antibiotics.
6
Exam trap — Orbital apex vs Superior orbital fissure vs Cavernous sinus: Orbital apex = CN II + III + IV + V1 + VI (vision loss present). SOF = III + IV + V1 + VI (no vision loss, no V2). CSS = III + IV + V1 + V2 + VI + sympathetic (V2 and Horner present).
7
Exam trap — Tolosa-Hunt vs lymphoma: Both can present as enhancing cavernous sinus mass on MRI. Tolosa-Hunt responds to steroids — but so does lymphoma. If symptoms recur on steroid taper, biopsy is mandatory to exclude lymphoma.
8
Exam trap — CCF and glaucoma: CCF raises IOP via elevated episcleral venous pressure. The IOP is often resistant to standard medical therapy. The clue is an elevated episcleral venous pressure with dilated, tortuous (arterialized) conjunctival vessels.

Oral-exam questions

  • Which cranial nerve is affected first in cavernous sinus lesions and why? — CN VI (abducens), because it runs freely through the centre of the cavernous sinus, unlike CN III, IV, V1, V2 which are embedded in the lateral wall.
  • What is pathognomonic of septic cavernous sinus thrombosis? — Bilateral involvement (spread via intercavernous sinuses connecting the two cavernous sinuses). A febrile patient with bilateral painful ophthalmoplegia = septic CST until proven otherwise.
  • How do you distinguish orbital apex syndrome from cavernous sinus syndrome? — Orbital apex involves CN II (visual loss) and spares CN V2. Cavernous sinus involves CN V2 (cheek numbness) and includes sympathetic dysfunction (Horner) but typically spares CN II.
  • What is the danger triangle of the face? — The area between the medial canthi of the eyes and the upper lip. Venous drainage from this area reaches the cavernous sinus via the valveless angular and ophthalmic veins, allowing facial infections to cause septic CST.
  • What is the Barrow classification? — Classification of carotid-cavernous fistulae: Type A = direct ICA-to-CS (high-flow); Types B, C, D = indirect/dural (low-flow). Type D (mixed ICA + ECA meningeal feeders) is the most common indirect type.
  • How does Tolosa-Hunt syndrome respond to treatment? — Dramatic pain relief within 72 hours of systemic corticosteroids (prednisolone 1 mg/kg/day). However, this response is NOT specific — lymphoma also responds to steroids. Biopsy if recurrent.
  • What is the pupil finding when both CN III and sympathetic fibres are damaged in CSS? — A mid-dilated, poorly reactive pupil — parasympathetic loss (CN III → mydriasis) is partially opposed by sympathetic loss (Horner → miosis), resulting in a mid-position pupil.
  • What is the most common source of septic CST? — Sphenoid sinusitis (most common), followed by ethmoid sinusitis, orbital cellulitis, dental infections, and facial furuncles.

Mnemonics

TOM CAT

T — Tumour (meningioma, pituitary, NPC, metastasis) O — Other vascular (aneurysm, CCF) M — Mucormycosis C — CST (septic/aseptic thrombosis) A — Autoimmune (Tolosa-Hunt, sarcoid, GPA, IgG4) T — Trauma (basal skull fracture → CCF)

Lateral Wall Nerves (Superior to Inferior)

III — CN III (oculomotor) — most superior in lateral wall IV — CN IV (trochlear) — below CN III V1 — Ophthalmic division of trigeminal V2 — Maxillary division of trigeminal — most inferior in lateral wall (CN VI runs through the CENTRE of the sinus — hence most vulnerable)

Comparison Tables

Orbital Apex vs Superior Orbital Fissure vs Cavernous Sinus Syndrome
CN II (optic)
Orbital Apex Syndrome
YES (visual loss)
Superior Orbital Fissure Syndrome
No
Cavernous Sinus Syndrome
No (unless secondary)
CN III
Orbital Apex Syndrome
Yes
Superior Orbital Fissure Syndrome
Yes
Cavernous Sinus Syndrome
Yes
CN IV
Orbital Apex Syndrome
Yes
Superior Orbital Fissure Syndrome
Yes
Cavernous Sinus Syndrome
Yes
CN V1
Orbital Apex Syndrome
Yes
Superior Orbital Fissure Syndrome
Yes
Cavernous Sinus Syndrome
Yes
CN V2
Orbital Apex Syndrome
No
Superior Orbital Fissure Syndrome
No
Cavernous Sinus Syndrome
YES (cheek numbness)
CN VI
Orbital Apex Syndrome
Yes
Superior Orbital Fissure Syndrome
Yes
Cavernous Sinus Syndrome
Yes
Sympathetic (Horner)
Orbital Apex Syndrome
No
Superior Orbital Fissure Syndrome
No
Cavernous Sinus Syndrome
YES
Key distinguishing feature
Orbital Apex Syndrome
Visual loss
Superior Orbital Fissure Syndrome
No V2, no Horner, no vision loss
Cavernous Sinus Syndrome
V2 + Horner present
Cavernous Sinus Syndrome by Aetiology
Septic CST
Onset
Acute (hours–days)
Pain
Severe
Fever
High
Bilateral
Yes (pathognomonic)
Key Investigation
CT sinuses + MRI/MRV
Treatment
IV antibiotics + sinus drainage
CCF (direct)
Onset
Acute (post-trauma)
Pain
Moderate
Fever
No
Bilateral
Rarely
Key Investigation
DSA (gold standard)
Treatment
Endovascular embolisation
CCF (indirect)
Onset
Gradual
Pain
Mild
Fever
No
Bilateral
Rarely
Key Investigation
Orbital Doppler + DSA
Treatment
Observation; embolise if persistent
Tolosa-Hunt
Onset
Subacute (days)
Pain
Severe
Fever
No
Bilateral
No
Key Investigation
MRI with gadolinium
Treatment
Systemic corticosteroids
Tumour
Onset
Insidious (weeks–months)
Pain
Mild/absent
Fever
No
Bilateral
Rarely
Key Investigation
MRI with gadolinium
Treatment
Surgery / radiation / chemo
Mucormycosis
Onset
Acute (days)
Pain
Severe
Fever
Variable
Bilateral
Rarely
Key Investigation
MRI + biopsy + KOH
Treatment
Amphotericin B + debridement

Self-Assessment (5)

MCQ

A 45-year-old woman presents with severe right-sided headache, right ptosis, and diplopia developing over 3 days. MRI shows enhancement of the right cavernous sinus. She is started on oral prednisolone and reports dramatic pain relief within 48 hours. What is the most likely diagnosis?

MCQ

Which cranial nerve is typically the FIRST to be affected in cavernous sinus lesions?

MCQ

A 60-year-old diabetic patient in ketoacidosis presents with rapidly progressive painful ophthalmoplegia, proptosis, and a black nasal eschar. What is the most appropriate first-line antifungal?

MCQ

A patient with cavernous sinus syndrome is found to have bilateral involvement with high fever and periorbital oedema. What is the most likely diagnosis?

MCQ

In the Barrow classification of carotid-cavernous fistulae, what is the most common type of indirect (dural) CCF?

References

  1. Kline LB, Hoyt WF. The Tolosa-Hunt syndrome. J Neurol Neurosurg Psychiatry. 2001;71(5):577-582.
  2. Barrow DL, Spector RH, Braun IF, et al. Classification and treatment of spontaneous carotid-cavernous sinus fistulas. J Neurosurg. 1985;62(2):248-256.
  3. Southwick FS, Richardson EP Jr, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore). 1986;65(2):82-106.
  4. Headache Classification Committee of the International Headache Society (IHS). ICHD-3: Tolosa-Hunt syndrome criteria. Cephalalgia. 2018;38(1):1-211.
  5. Kanski JJ, Bowling B. Clinical Ophthalmology: A Systematic Approach, 8th Edition

Related Content

CN III PalsyCN VI PalsyHorner SyndromeMyasthenia GravisPituitary Tumours
Was this helpful?

Topic complete

Continue to another topic when you are ready.

Previous topic← Anterior ischemic optic neuropathyNext topicChiasmal syndromes